key: cord-0937526-052jj77w
authors: Muyayalo, Kahinho P.; Huang, Dong‐Hui; Zhao, Si‐Jia; Xie, Ting; Mor, Gil; Liao, Ai‐Hua
title: COVID‐19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcomes
date: 2020-07-31
journal: Am J Reprod Immunol
DOI: 10.1111/aji.13304
sha: a60096292cc2ed77d9867d2ec31b1c67769da0e0
doc_id: 937526
cord_uid: 052jj77w

Caused by a novel type of virus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), coronavirus disease 2019 (COVID‐19) constitutes a global public health emergency. Pregnant women are considered to have a higher risk of severe morbidity and even mortality due to their susceptibility to respiratory pathogens and their particular immunologic state. Several studies assessing SARS‐CoV‐2 infection during pregnancy reported adverse pregnancy outcomes in patients with severe conditions, including spontaneous abortion, preterm labor, fetal distress, cesarean section, preterm birth, neonatal asphyxia, neonatal pneumonia, stillbirth, and neonatal death. However, whether these complications are causally related to SARS‐CoV‐2 infection is not clear. Here, we reviewed the scientific evidence supporting the contributing role of Treg/Th17 cell imbalance in the uncontrolled systemic inflammation characterizing severe cases of COVID‐19. Based on the recognized harmful effects of these CD4(+) T‐cell subset imbalances in pregnancy, we speculated that SARS‐CoV‐2 infection might lead to adverse pregnancy outcomes through the deregulation of otherwise tightly regulated Treg/Th17 ratios, and to subsequent uncontrolled systemic inflammation. Moreover, we discuss the possibility of vertical transmission of COVID‐19 from infected mothers to their infants, which could also explain adverse perinatal outcomes. Rigorous monitoring of pregnancies and appropriate measures should be taken to prevent and treat early eventual maternal and perinatal complications.

disease (pneumonia); and approximately 5% eventually develop acute respiratory distress syndrome (ARDS), or multiple organ failure. 5 Elderly patients and those with comorbidities (hypertension, diabetes, cardiovascular disease, and cerebrovascular disease) are at risk of developing the severe form of COVID-19 and have a high mortality rate. 6, 7 Due to their singular immune characteristics and susceptibility to respiratory pathogens, pregnant women infected with SARS-CoV-2 should be considered to present a higher risk for severe morbidity and even mortality. 8 Numerous studies have reviewed COVID-19 in pregnant women and reported adverse pregnancy outcomes among these patients. 9 The maternal adverse pregnancy outcomes reported in these studies included spontaneous abortion, 10, 11 premature rupture of membranes, 10,12 preterm labor, [9] [10] [11] [12] fetal distress, 12 and cesarean section. [9] [10] [11] [12] Among the neonates of COVID-19 mothers, preterm birth, [9] [10] [11] [12] neonatal asphyxia, 10,12 pneumonia, 9, 12 low birth weight, 9, 12 stillbirth, and neonatal death 12 have been reported. These adverse pregnancy outcomes can be attributed to the progression of the disease toward the severe stage (ARDS, septic shock, and multiple organ failure) or are linked to the challenge of treating pregnant women considering the effects of certain therapeutic protocols on the fetus. However, whether these outcomes are causally related to the effects of SARS-CoV-2 infection during pregnancy requires further clarification.

In this review, we show that the uncontrolled systemic inflammatory state characterizing COVID-19 involves an increased number of Th17 cells, and a decrease in Treg cell levels, which could contribute to the occurrence of adverse pregnancy outcomes observed in infected pregnant women.

SARS-CoV-2 is a positive-sense single-stranded RNA virus (betacoronavirus genus) in the same subgenus as the severe acute respiratory syndrome (SARS) virus, but in a different clade. 13 This novel virus likely originated in chrysanthemum bats; the pangolin is reported to be an intermediate host between bats and humans; and person-to-person viral transmission is thought to occur mainly via respiratory droplets. 14 The incubation time varies from 2 to 14 days after infection. Clinically, SARS-CoV-2 infection can be asymptomatic or can result in mild to severe symptomatic disease. 15 Both innate and adaptive immune cells synergistically participate in antiviral responses during SARS-CoV-2 infection. 16 The virus uses a spike glycoprotein (S) protein to bind its receptor (angiotensin-converting enzyme 2 (ACE2) receptor) on target cells. 17 The virion then enters the host cells (endocytosis) and releases its RNA genome, which constitutes a pathogen-associated molecular pattern (PAMP). Inside host cells (immune or non-immune cells), the viral RNA (PAMP) is recognized by pathogen recognition receptors (PRRs), which collect the specific signal adapter protein and activate IRF3 and IRF7 before being translocated to the nucleus to promote the synthesis of type I interferons (IFNs). 17 In infected innate immune cells (macrophages and dendritic cells (DCs)), type I IFNs lead to an increase in antigen presentation activity and production of immune response mediators, such as cytokines and chemokines ( Figure 1A ). 18 Antigen presentation to T cells induces T-cell activation and differentiation, including the production of cytokines associated with different T-cell subsets (such as Th17), followed by a massive release of cytokines for immune response amplification ( Figure 1B ). 19 In adaptive immunity, type I IFNs may also act by increasing antibody production by B cells (IgM and IgG) and amplify the effector function of T cells. 18 Type I IFNs produced by infected non-immune cells (fibroblasts and epithelial cells) induce an intracellular antimicrobial program that limits the spread of infectious agents in infected and neighboring cells. 18 Pulmonary and systemic inflammatory responses associated with COVID-19 are often triggered by the innate immune system when it recognizes the viruses. 20 Depending on the general health and genetic background (HLA) of patients, 21 this immune response promotes virus clearance, inhibits viral replication, induces tissue repair, and triggers a prolonged adaptive immune response against the infectious agent. 20

When patients are not in good general health, or when they are susceptible to infections (unfavorable genetic background), protective immune responses can be impaired. 21 The virus will propagate, and massive destruction of the affected tissues will occur, especially in organs that have high ACE2 expression, such as the lungs, intestines, and kidneys. Lung inflammation is the leading cause of life-threatening respiratory disorders when at a severe stage of disease. 22 Indeed, prior reports show that at the critical stage of COVID-19, ARDS is the main cause of death. 23 which is frequently fatal ( Figure 1E ).

During SARS-CoV-2 infection, dysregulation of the immune system and involving T cells has been reported. 24 Differences in blood cell counts are observed between severe and non-severe groups. Compared with non-severe patients, most severe cases of COVID-19 have lower percentages of monocytes, eosinophils, and basophils. 24, 25 Moreover, they exhibit lower lymphocyte counts (lymphopenia) ( Figure 1C ), higher leukocyte and neutrophil numbers, and, consequently, higher neutrophil-to-lymphocyte ratio (NLR). 24, 25 Lymphopenia in COVID-19 patients has been reported in several other studies. 22,26-30 B cells, T cells, and NK cell numbers are significantly decreased in patients with COVID-19, and this is more evident in severe cases. 22, 24, 31, 32 However, T-cell numbers are more affected than other cell types. 24 Analyzing different T-cell subsets, Qin et al 24 found that both suppressor T cells (CD3 + CD8 + ) and helper T cells (CD3 + CD4 + ) were below normal levels. In addition, the percentage of naïve helper T cells (CD3 + CD4 + CD45RA + ) increased, while memory helper T cells (CD3 + CD4 + CD45RO + ) decreased in severe cases, indicating the severity of immune system impairment. Although the number of T cells decreased, their functions remained within the normal range 24 or were even hyperactivated, as evidenced by the high proportion of HLA-DR (CD4) and CD38 (CD8) double-positive fractions. 22 The impaired adaptive immune response observed in severe F I G U R E 1 Treg/Th17 cell imbalance and related outcomes in severe COVID-19 pregnant women A, Infected innate immune cells (macrophages and dendritic cells) produce type I interferons (IFNs). Type I IFNs lead to an increase in antigen presentation activity and the production of cytokines and chemokines to ensure pathogen clearance and help to mobilize adaptive immune responses. B, In the case of prolonged inflammation, continual activation and recruitment of effector cells might establish a feedback loop that perpetuates inflammation and results in the release of large amounts of pro-inflammatory cytokines and chemokines by immune effector cells (cytokine storm). C, In this severe condition, adaptive immune cells, particularly T cells, are impaired. B cells, T cells, and NK cell numbers are significantly decreased (lymphopenia). Although the lymphopenia also involves CD4 + T cells, the proportion of Treg cells and Th17 cells is affected by SARS-CoV-2 in a different way. Indeed, the increased circulating IL-6 levels induce the differentiation of naïve CD4 + T cells toward Th17 cells, while inhibiting Treg cells, leading to Treg/Th17 ratio imbalance. D, IL-17 released by Th17 cells activates other downstream cascades involving cytokines (G-CSF, IL-1β, IL-6, TNF-α) and chemokines (CXCLs), followed by the recruitment of more effector cells and massive release of inflammatory cytokines that amplify the uncontrolled systemic inflammation (cytokine storm). E, Uncontrolled systemic inflammation might provoke acute respiratory distress syndrome (ARDS), multiorgan failure, and death. F, Uncontrolled systemic inflammation might also cause adverse pregnancy outcomes (miscarriage, preterm birth, fetal distress, preeclampsia, and intrauterine growth restriction). G, In the case of vertical transmission of SARS-CoV-2, anticipated complications might involve infection of the placenta (chorioamnititis, premature membrane rupture), and adverse neonatal outcomes, such as stillbirth, neonatal asphyxia, pneumonia, and neonatal death COVID-19 patients might be caused by the pulmonary recruitment of immune cells from peripheral blood and the infiltration of lymphocytes into the airways as suggested by several authors. [33] [34] [35] [36] The release of pro-inflammatory cytokines (such as IFN-γ and IL-6) and chemokines (such as CCL2 and CXCL10) attracts immune cells, notably monocytes and T lymphocytes, but not neutrophils, from the blood to the infected site. 22, 37 This will result in lymphopenia, eosinopenia, and increased neutrophil-lymphocyte ratio in peripheral blood, 38, 39 as well as ARDS in COVID-19 patients. 35 In summary, these data show that, in its severe stage, the pathogenesis of COVID-19 involves impaired adaptive immune responses and uncontrolled release of pro-inflammatory cytokines, which cause systemic inflammation, ADRS, multiple organ failure, and finally lead to death.

Although helper T-cell (CD3 + CD4 + ) levels were below normal, the proportion of Treg cells and Th17 cells was affected by SARS-CoV-2 in different ways. Indeed, severe COVID-19 patients had a significant decrease in Treg cell levels (CD3 + CD4 + CD25 + CD127low + ), 24, 40 increased levels of Th17 cells (CCR6 + Th17), 22,41 with a consequent decrease in the Treg/Th17 cell ratio ( Figure 1C ).

Treg and Th17 cells are part of the complex machinery that constitutes the immune system. The differentiation of Th17 and Treg cells from naïve CD4 + T cells is mediated by TGF-β. However, in the presence of IL-6 or IL-21 (together with TGF-β), naïve CD4 + T cells differentiate into Th17 cells. 42 These two CD4 + T-cell subsets have different actions. 43 Th17 cells are mainly characterized by their production of inflammatory cytokines such as IL-17A, 42 which activates target cells and induces chemokine (C-X-C motif) ligands (CXCLs). 44 CXCLs then attract myeloid cells such as neutrophils to infected or injured tissues. 44 In contrast, Treg cells express anti-inflammatory cytokines (IL-4, IL-10, and TGF-β) and control excessive immune responses. 45, 46 The Treg/Th17 balance plays an important role in the severity of lung injury 47 and in uncontrolled systemic inflammation characterizing acute lung injury (ALI)/ ARDS ( Figure 1C ). 48 In patients with severe COVID-19, the increase in Th17 cells is accountable, at least in part, to severe immune injury in such patients. 22 Indeed, among the pro-inflammatory cytokines iden- (Figure 1D) , and matrix metalloproteinases. 19, 41, 49, 50 Treg cells play a crucial role in weakening or dampening overactive innate immune responses for the maintenance of self-tolerance and immune homeostasis during viral. 51, 52 In severe COVID-19 cases, decreased Treg numbers indicate insufficient regulation of pro-inflammatory immune responses that may further aggravate hyperinflammation and tissue injury. 53 In addition, several studies have reported a significant increase in IL-6 levels among other elevated inflammatory cytokines in COVID-19 patients, with significantly higher levels in severe rather than in mild cases. 16, 24, 30, 54, 55 IL-6 is a pleiotropic cytokine with mainly a pro-inflammatory function affecting several processes including immunity, tissue repair, and metabolism. 56 Indeed, in response to tissue damage and infections, 57 

In a healthy pregnancy, the immune system not only recognizes and fights infections (defense), but also regulates undesired immune responses against tissue self-antigens or harmless non-self-organisms An appropriate balance between Treg/Th17 cells is critical for healthy fetal implantation and pregnancy development. 63 During healthy pregnancy, the Treg/Th17 ratio shifts in favor of Treg cells.

Treg cells also proliferate systemically, as well as at the fetal-maternal interface, to ensure maternal-fetal immune tolerance and successful pregnancy. 64 In contrast, uncontrolled Th17 cell proliferation is unfavorable because it is associated with fetal allograft rejection at the feto-maternal interface. 43 The dysregulation of this tight balance between Treg and Th17 cells has been shown to be involved in the pathogenesis of adverse pregnancy outcomes. 63 Indeed, decreased Treg cell numbers [65] [66] [67] [68] [69] [70] [71] and increased Th17 cell percentages 68, [72] [73] [74] are associated with pregnancy complications such as miscarriage, preeclampsia (PE), and preterm labor ( Figure 1F ).

The pathogenesis of severe COVID-19 involves deregulation of the Treg/Th17 cell ratio toward an increase in Th17 cells, resulting in uncontrolled systemic inflammation. Thus, in SARS-CoV-2-infected pregnant women, Treg/Th17 cell imbalance might be potentially associated with adverse pregnancy outcomes such as pregnancy loss, preterm birth, and PE. Nevertheless, further investigations are required to validate their causal relationship.

In COVID-19-infected pregnant women, abortion or preterm deliv- 

The authors declare no conflicts of interest.

https://orcid.org/0000-0001-7055-4138

Ai-Hua Liao https://orcid.org/0000-0001-8533-8315

Severe acute respiratory syndrome-related coronavirus: the species and its viruses -a statement of the Coronavirus Study Group

COVID-19 coronavirus pandemic

detai l/30-01-2020-state ment-on-the-secon d-meeti ng-of-the-inter natio nal-healt h-regul ation s-(2005)-emerg ency-commi ttee-regar ding-the-outbr eak-of-novel

WHO declares COVID-19 a pandemic

COVID-19: immunopathology and its implications for therapy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prediction for progression risk in patients with COVID-19 pneumonia: the CALL Score

Why are pregnant women susceptible to COVID-19? An immunological viewpoint

COVID-19 infection during pregnancy: a systematic review to summarize possible symptoms, treatments, and pregnancy outcomes. medRxiv

Coronavirus disease 2019 (COVID-19) in pregnant women: a report based on 116 cases

Clinical characteristics of pregnant women with Covid-19 in Wuhan, China

Pregnancy outcomes, newborn complications and maternal-fetal transmission of SARS-CoV-2 in women with COVID-19: a systematic review

Coronavirus disease 2019 (COVID-19)

COVID-19-new insights on a rapidly changing epidemic

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Regulation of type I interferon responses

Coronavirus infections and immune responses

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

COVID-19 infection: the perspectives on immune responses

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Molecular immune pathogenesis and diagnosis of COVID-19

Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. medRxiv

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou

Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel?

The trinity of COVID-19: immunity, inflammation and intervention

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Clinical characteristics of COVID-19 in China. Reply

Nonpharmaceutical interventions and epidemic intensity during the 2019 novel coronavirus disease pandemic

The laboratory tests and host immunity of COVID-19 patients with different severity of illness

TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib

The balance of Th17 versus Treg cells in autoimmunity

Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion

Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases

Regulatory T cells in autoimmune neuroinflammation

Identifying immune mechanisms mediating the hypertension during preeclampsia

Ultrafine particles in the airway aggravated experimental lung injury through impairment in Treg function

Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications

T Helper 17 cells as pathogenic drivers of periodontitis

Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases

FOXP3+ regulatory T cells in the human immune system

Age-dependent dysregulation of innate immunity

Covid-19 and immunomodulation in IBD

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Macrophage cytokines: involvement in immunity and infectious diseases

IL-6 in inflammation, immunity, and disease

Versatile functions for IL-6 in metabolism and cancer

Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Transforming growth factor-beta induces development of the T(H)17 lineage

Human seminal plasma fosters CD4(+) regulatory T-cell phenotype and transforming growth factor-beta1 expression

The T helper type 17/regulatory T cell paradigm in pregnancy

The tolerogenic function of regulatory T cells in pregnancy and cancer

Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model

Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia

Activated T lymphocytes in pre-eclampsia

The balance of the immune system between T cells and NK cells in miscarriage

Low levels of circulating T-regulatory lymphocytes and short cervical length are associated with preterm labor

Proportional changes of CD4+CD25+Foxp3+ regulatory T cells in maternal peripheral blood during pregnancy and labor at term and preterm

The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia

The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia

A role for IL-17 in induction of an inflammation at the fetomaternal interface in preterm labour

TH17 cells in human recurrent pregnancy loss and pre-eclampsia

Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: a review

Unlikely SARS-CoV-2 vertical transmission from mother to child: a case report

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Antibodies in infants born to mothers with COVID-19 pneumonia

Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn

Risks associated with viral infections during pregnancy

The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study

Severe COVID-19 during pregnancy and possible vertical transmission

COVID-19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcomes